Type: News Releases
Cascadian, a clinical-stage biopharmaceutical company, develops innovative products for cancer treatment. The company’s most advanced program, tucatinib, is currently being evaluated in a randomized global pivotal trial for patients with HER2-positive metastatic breast cancer. Seattle Genetics, a biotechnology company, focuses on developing novel antibody based therapies for cancer treatment.
The Reed Smith deal team included Jennifer W. Cheng (New York); Paul Jaskot, Howard Shecter, John Martini, Megan Cribbs, Samantha Peruto, Kristin Antario, and Nicole Martini (Philadelphia); Leo Hitt and Debra Dermody (Pittsburgh); and John McWilliams (Tysons Corner).
Click here to read the Cascadian news release.